Two Alzheimer’s immunotherapy drugs flunk in four studies
Posted on: 22/01/2014 - 22:00
Two investigational Alzheimer’s immunotherapies failed to show any benefit in a series of phase III trials comprising more than 4,000 patients. Neither bapineuzumab, which targets soluble and...
Field of Interest: Geriatrics
Type: News Item